SU2C Scientific Research Teams
Lewis C. Cantley, Ph.D.Scientific Research Team:
Targeting PI3K in Women’s Cancers
Lewis C. Cantley, Ph.D., is a professor of systems biology at Harvard Medical School and chief of the division of signal transduction at Beth Israel Deaconess Medical Center, a major teaching hospital of Harvard Medical School in Boston.
Cantley joined the faculty of Harvard Medical School in 1992, when he was also appointed to chief of the division of signal transduction in the department of medicine at the former Beth Israel Hospital. In 2007, he was appointed director of the cancer center.
A summa cum laude graduate of West Virginia Wesleyan College, Cantley obtained a doctorate in biophysical chemistry from Cornell University in 1975. He completed postdoctoral research at Harvard from 1975 through 1978 when he joined the department of biochemistry and molecular biology as an assistant professor. Prior, Cantley was professor of physiology at Tufts University School of Medicine. He is a member of the American Academy of Arts and Sciences and the National Academy of Sciences, and serves on the editorial boards of the journals Cell and the Journal of Cell Biology. He is the recipient of the 2005 Pezcoller Foundation-American Association for Cancer Research International Award for Cancer Research, for his leadership in the field of signal transduction, including the discovery of phosphoinositide 3-kinase (PI3K).
In addition, research from Cantley’s laboratory has revealed that PI3K is also a significant factor in insulin signaling and in immune cell signaling. As a result, pharmaceutical intervention in the PI3K pathway is being explored in a variety of diseases, such as cancer, diabetes and immune diseases.